M. Pickard

发表

A Flexible Method Using a Parametric Bootstrap for Reducing Bias in Adaptive Designs With Treatment Selection

Mark Chang, M. Pickard, 2014 .

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019, European journal of cancer.

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

G. Mulligan, A. Pavlick, O. Hamid, 2016, Investigational New Drugs.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Jeffrey W. Clark, G. Mulligan, G. Shapiro, 2015, Clinical Cancer Research.

Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.

E. Lightcap, Jie Yu, J. Blank, 2010, Cancer research.

Gene expression profiles: creating new perspectives in arthritis research.

E. Grant, J. Gutiérrez-Ramos, M. Briskin, 2002, Arthritis and rheumatism.

The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study

Peter G. Smith, D. DeAngelo, F. Giles, 2010 .

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

FcepsilonRI-dependent gene expression in human mast cells is differentially controlled by T helper type 2 cytokines.

J. Boyce, J. Gutiérrez-Ramos, K. Price, 2003, The Journal of allergy and clinical immunology.

PKC-θ-Deficient Mice Are Protected from Th1-Dependent Antigen-Induced Arthritis

M. Silva, B. Jaffee, S. Chandra, 2006, The Journal of Immunology.

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

G. Mulligan, A. Jakubowiak, S. Lonial, 2009 .

Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma

C. Berking, D. Schadendorf, K. Flaherty, 2017 .

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2018, The Lancet. Oncology.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

G. Mulligan, D. Esseltine, P. Sonneveld, 2012, Blood.

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020, European journal of cancer.

Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events

P. Libby, P. Ridker, J. Lillie, 2006, Circulation.

A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development

K. Venkatakrishnan, M. Pickard, Lisa L. Moltke, 2010, Clinical pharmacokinetics.

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors

R. Sullivan, P. Ascierto, R. Dummer, 2020, Clinical Cancer Research.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dirk Schadendorf, Reinhard Dummer, Naoya Yamazaki, 2018, The Lancet. Oncology.

Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways

E. Lightcap, David C. Bouck, Peter G. Smith, 2014, Molecular Cancer Therapeutics.

Cancer Biology and Signal Transduction Nedd 8-Activating Enzyme Inhibitor MLN 4924 Provides Synergy with Mitomycin C through Interactions with ATR , BRCA 1 / BRCA 2 , and Chromatin Dynamics Pathways

E. Lightcap, David C. Bouck, Peter G. Smith, 2014 .

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2020, Journal of Clinical Oncology.

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019, Journal of Clinical Oncology.

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

A. Berger, J. Bolen, O. Tayber, 2011, Clinical Cancer Research.

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019 .

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2018 .

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2021 .

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

G. Mulligan, R. Fisher, M. Fleming, 2010, Leukemia & lymphoma.

FcεRI-dependent gene expression in human mast cells is differentially controlled by T helper type 2 cytokines

J. Boyce, J. Gutiérrez-Ramos, K. Price, 2003 .

PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis.

B. Jaffee, S. Chandra, D. Picarella, 2006, Journal of immunology.

A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).

C. Berking, A. Gesierich, P. Ascierto, 2020 .

Estimation methods in adaptive treatment-selection designs

Michael Pickard, M. Pickard, 2015 .

1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2017 .